In general they are not regaining function but they deteriorated at a slower pace. The data presented is a group analysis, there is significant differences in disease progression in individual patients. Survival data is fantastic but it is compared to one patient death in our study. Another death, particularly near term would change the slope significantly.
Ann: PharmAust's Phase 1 Study Data Presented at Major Conference, page-8
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.015(7.69%) |
Mkt cap ! $93.45M | |||
| Open | High | Low | Value | Volume |
| 20.0¢ | 21.5¢ | 19.5¢ | $459.0K | 2.222M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 103700 | 20.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 127225 | 3 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| PAA (ASX) Chart |